製品番号: HY-15354

Copy Link Print Information

TSAO-T

TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 141781-17-1
分子式: C₂₄H₄₃N₃O₈SSi₂
分子量:589.85

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

TSAO-T 構造式

CAS 番号: 141781-17-1

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection^[1].

HIV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	12 μM Compound: TSAO-T	Cytotoxicity against human CEM cells after 4 days Cytotoxicity against human CEM cells after 4 days	[PMID: 21880398]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures	[PMID: 15974581]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days	[PMID: 18316194]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 18353641]
CCRF-CEM	EC₅₀	>10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>20 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>20 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	>3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>3.3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>4 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	>4 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	>50 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.01 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.03 μg/mL Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication	[PMID: 18353641]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	0.07 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.22 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.23 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.4 μM Compound: TSAO-T	Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	1.9 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	2 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	3 μM Compound: TSAO-T	Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	4.6 μM Compound: TSAO-T	Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
Huh-7	CC₅₀	>100 μM Compound: TSAO-T	Cytotoxicity against human HuH7 cells after 72 hrs Cytotoxicity against human HuH7 cells after 72 hrs	[PMID: 21880398]
Huh-7	EC₅₀	14 μM Compound: TSAO-T	Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 21880398]
Lymphocyte	EC₅₀	0.034 μg/mL Compound: 12a	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	14 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures	[PMID: 15974581]
MT4	CC₅₀	14 μM Compound: TSAO-T	Inhibition of MT4 cell viability Inhibition of MT4 cell viability	[PMID: 16884295]
MT4	CC₅₀	7.7 μg/mL Compound: 12a	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	EC₅₀	>20 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 in MT4 cells Antiviral activity against HIV1 in MT4 cells	[PMID: 16884295]

化学情報

CAS 番号 141781-17-1
分子量 589.85
分子式 C₂₄H₄₃N₃O₈SSi₂
SMILES

O=C1NC(C(C)=CN1[C@@H]([C@@H]2O[Si](C)(C(C)(C)C)C)O[C@H](CO[Si](C)(C(C)(C)C)C)[C@@]32C(N)=CS(O3)(=O)=O)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (273 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Bonache MC, et al. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J Med Chem. 2005 Oct 20;48(21):6653-60. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

TSAO-T

HIV アイソフォーム固有の製品をすべて表示